Table 3.
The clinic study about the concentration of SFRPs in patients with cardiovascular disease.
| Genotype | Study population | Concentration of SFRPs | References |
|---|---|---|---|
| SFRP1 | Cardiovascular disease: Controls (n=157); Patients with cardiovascular events (n=). | Control: 2609.0 [1926.1-3234.9] pg/mL; CVD: 3221.8 [2352.8-3811.0] pg/mL. | (159) |
| SFRP3 | HF study: Controls (n=25); HF patients (n= 153). | Control:1.83 (1.40, 2.46) ng/mL; HF patients: 2.83 (2.46, 3.62) ng/mL. | (167) |
| SFRP4 | Cardiovascular disease: CAD patients (n=504). | Control: 12.21 (3.64 – 41.2) μg/L; CAD patients: 11.21 (9.17, 13.86) μg/L. | (10) |
| SFRP4 | Cardiovascular disease: Non-CAD(n=30); CAD (n=30). | non-CAD: 14.5 ± 2.3 ng/mL. CAD: 16.8 ± 3.3 ng/mL; | (161) |
| SFRP4 | Cardiovascular disease: Control (n=35); DM (n=37); CAD (n=34); CAD+DM (n=36). | Control:1.41 (1.24–1.67) ng/mL; DM: 1.70 (1.51–2.45) ng/mL; CAD: 1.58 (1.31–2.55) ng/mL; CAD+DM: 2.02 (1.47–3.47) ng/mL. | (162) |
| SFRP5 | Cardiovascular disease: non-CAD (n=57); CAD (n=128). | non-CAD: 52.4 [29.6] ng/mL; CAD: 47.7 [26.6] ng/mL; | (163) |
| SFRP5 | Cardiovascular disease: non-CAD (n=29); CAD (n=58). | non-CAD: 21.27±3.38 ng/mL; CAD: 16.23±3.17 ng/mL. | (165) |
| SFRP5 | MI study: no-CAD (n=35); STEMI (n=85). | no-CAD: 19.8 ng/mL; STEMI: 23.3 ng/mL. | (156) |
CAD, Cardiovascular disease; DM, Diabetes mellitus; HF, Heart failure; MI, Myocardial infarction; SFRP, Secreted frizzled-related protein; STEMI, ST-Elevation Myocardial Infarction.